Patent · US Active

Formulation of an antibody and use thereof

US11433029B2 · kind B2 · utility

0Cited by

0References

29Claims

0Family size

Assignee

Takeda Pharmaceutical Company Limited · JP

Inventors

Markus Rast · Radolfzell, DE
Wolfgang Ise · Konstanz, DE
Gerhard Becker · Neckargemünd, DE
Peter Skufca · Stockach, DE
Henning Gieseler · Erlangen, DE

Key dates

Filing date	Mar 17, 2014
Grant date	Sep 6, 2022
Priority date	—
Expiry date	May 17, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/24
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides a method for preparation of a lyophilized formulation of an anti-CD 20 antibody as well as to a lyophilized formulation of an anti-CD 20 antibody, comprising an anti-CD 20 antibody and having a residual moisture content in the range of 1% to 10%. The present invention also relates to the reconstituted formulation obtained by the method described herein, the use of said antibody formulation as a medicament, the use of the lyophilized formulation for the preparation of a medicament and a method of treating a patient.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.